EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Study on Absorption, Distribution and Excretion of a New Candidate Compound XYY-CP1106 against Alzheimer’s Disease in Rats by LC-MS/MS

Zili Guo iD, Bianbian Gao, Miaoliang Fan, Lisha Chen, Changjun Zhang, Xianrui Liang iD, Weike Su, Yuanyuan Xie

Molecules · 2023

DOI: 10.3390/molecules28052377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Zili Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Key Laboratory of Pharmaceutical Engineering of Zhejiang Province, Collaborative Innovation Center of Yangtze Riv…. Hauptthemen laut MEDLINE: Alzheimer Disease, Body Fluids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

XYY-CP1106, a candidate compound synthesized from a hybrid of hydroxypyridinone and coumarin, has been shown to be remarkably effective in treating Alzheimer’s disease. A simple, rapid and accurate high-performance liquid chromatography coupled with the triple quadrupole mass spectrometer (LC-MS/MS) method was established in this study to elucidate the pharmacokinetics of XYY-CP1106 after oral and intravenous administration in rats. XYY-CP1106 was shown to be rapidly absorbed into the blood (Tmax, 0.57–0.93 h) and then eliminated slowly (T1/2, 8.26–10.06 h). Oral bioavailability of XYY-CP1106 was (10.70 ± 1.72)%. XYY-CP1106 could pass through the blood–brain barrier with a high content of (500.52 ± 260.12) ng/g at 2 h in brain tissue. The excretion results showed that XYY-CP1106 was mainly excreted through feces, with an average total excretion rate of (31.14 ± 0.05)% in 72 h. In conclusion, the absorption, distribution and excretion of XYY-CP1106 in rats provided a theoretical basis for subsequent preclinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBody FluidsRatsAnimalsChromatography, LiquidTandem Mass SpectrometryTissue DistributionChromatography, High Pressure LiquidFecesAdministration, Oral

Stichwörter der Autor:innen

Alzheimer’s diseaseLC-MS/MSXYY-CP1106excretion studypharmacokineticstissue distribution

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Key Laboratory of Pharmaceutical Engineering of Zhejiang Province, Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technolo…
  • Interdisciplinary Research Academy, Zhejiang Shuren University, Hangzhou 310015, China.

ORCID-Profile: Zili Guo, Xianrui Liang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, Z., Gao, B., Fan, M., Chen, L., Zhang, C., Liang, X., Su, W., & Xie, Y. (2023). Study on Absorption, Distribution and Excretion of a New Candidate Compound XYY-CP1106 against Alzheimer’s Disease in Rats by LC-MS/MS. Molecules. https://doi.org/10.3390/molecules28052377

Vancouver

Guo Z, Gao B, Fan M, Chen L, Zhang C, Liang X, et al. Study on Absorption, Distribution and Excretion of a New Candidate Compound XYY-CP1106 against Alzheimer’s Disease in Rats by LC-MS/MS. Molecules. 2023. doi:10.3390/molecules28052377

BibTeX
@article{Guo2023,
  author = {Guo, Zili and Gao, Bianbian and Fan, Miaoliang and Chen, Lisha and Zhang, Changjun and Liang, Xianrui and Su, Weike and Xie, Yuanyuan},
  title = {Study on Absorption, Distribution and Excretion of a New Candidate Compound XYY-CP1106 against Alzheimer’s Disease in Rats by LC-MS/MS},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28052377}
}
Kostenlos starten →